17 Sep Does PCSK9 Genetic Variation Help Predict Risk of Sepsis?
MedicalResearch.com Interview with:
QiPing Feng, PhD
Division of Clinical Pharmacology
Department of Medicine
Vanderbilt University Medical Center
MedicalResearch.com: What is the background for this study?
Response: Sepsis is one of the leading causes of hospital mortality. Yet, there are no specific effective treatments for it. Recent information suggests that drugs that inhibit proprotein convertase subtilisin kexin type 9 (PCSK9) could have potential as a new treatment for sepsis.
We used a genetic approach to test if variation in PCSK9 affected the risk of sepsis.
In patients admitted to hospital with infection, neither variants in the PCSK9 gene nor predicted expression of PCSK9 were associated with risk of sepsis or poorer outcomes after sepsis.
MedicalResearch.com: What are the main findings?
Response: Our study, using a genetic approach, suggests that PCSK9 does not affect the risk of sepsis or its outcomes.
MedicalResearch.com: What should readers take away from your report?
Response: Although there was no association between PCSK9 and sepsis in our study, clinical trials with drugs that inhibit PCSK9 will be required to provide a definite answer.
Feng Q, Wei W, Chaugai S, et al. A Genetic Approach to the Association Between PCSK9 and Sepsis. JAMA Netw Open. Published online September 11, 20192(9):e1911130. doi:10.1001/jamanetworkopen.2019.11130
The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.